Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia.
Anouchka P LaurentAurélie SiretCathy IgnacimouttouKunjal PanchalM'Boyba DiopSilvia JenniYi-Chien TsaiDamien RoosweilZakia AidNais PradeStephanie LagardeDamien PlassardGaëlle PierronEstelle DaudigeosYann LecluseNathalie M DroinBeat C BornhauserLaurence C CheungJohn D CrispinoMuriel GaudryOlivier A BernardElizabeth MacintyreCarole Barin BonnigalRishi Sury KotechaDidier FrappazPaola BalleriniJean-Pierre BourquinEric DelabesseThomas MercherSebastien MalingePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Altogether, using novel and suitable PDX models, this study indicates that RAS/MAPK pathway inhibition represents a promising strategy to improve the outcome of Down syndrome children with B-cell precursor leukemia.